Epoxytigliane modulation of dermal fibroblast-myofibroblast wound healing responses mediate enhanced anti-scarring properties via classical protein kinase C activation (Supplementary Data)

Published: 30 September 2026| Version 2 | DOI: 10.17632/m5f5nbwnw2.2
Contributor:
Ryan Moseley

Description

Epoxytiglianes are a novel class of diterpene esters isolated from a native Australian rainforest plant, Fontainea picrosperma (Euphorbiaceae). Prototype epoxytigliane, EBC-46 (tigilanol tiglate), possesses potent anti-cancer properties and is currently in clinical development as a human and veterinary tumor treatment, in part mediated via the activation of classical protein kinase C (PKC) isoforms. EBC-46 also stimulates exceptional dermal wound healing in vivo upon tumor destruction, manifested as accelerated wound closure and minimal scar formation. However, the mechanisms underlying these anti-scarring responses are poorly understood. The data presented provides supplementary information to our manuscript, demonstrating the limited effects of EBC-46 and analogue, EBC-211, have on the migratory responses of human dermal fibroblasts. Specifically, the data shows the effects of EBC-46 and EBC-211 on in vitro scratch wound repopulation (automated Time-Lapse Confocal Microscopy movies over 48 h periods).

Files

Institutions

Categories

Drug Development, Scarring, Collagen, Matrix Metalloproteinase, Fibrosis, Extracellular Matrix, Myofibroblast, Natural Compound, Hyaluronic Acid

Funders

  • QBiotics Group
  • Life Sciences Research Network Wales

Licence